ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Completion of Acquisition or Disposition of AssetsItem 2.01 of the Original Filing (the “Transactions”), the Company is filing this Form 8-K/A to provide the unaudited pro forma condensed combined financial statements of the Company after giving effect to the Transactions, as required by Item 9.01(b) of Form 8-K. This information was not included in the Original Filing.
Item 9.01Financial Statements and Exhibits
(b)Pro Forma Financial Information.
|
(1) |
The unaudited pro forma condensed combined balance sheet of the Company as of September 30, 2017, and the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2016 and for the nine months ended September 30, 2017, and the related notes thereto, are attached hereto as Exhibit 99.2. |
(d) Exhibits
Exhibit No.Description
***
Ultragenyx Pharmaceutical Inc. ExhibitEX-99.2 2 rare-ex992_6.htm EX-99.2 rare-ex992_6.htm Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information combines the historical consolidated financial information of Ultragenyx Pharmaceutical Inc. (the Company or Ultragenyx) and Dimension Therapeutics,…To view the full exhibit click here
About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.
